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ABSTRACT
The role of different lipid species such as free fatty acids and sphingolipids in non-alcoholic fatty liver disease 
(NAFLD) has been extensively studied during the last decade. In addition, free cholesterol accumulation in 
hepatocytes plays a crucial role in the transition from steatosis to steatohepatitis. However, the contribution 
of these lipids to NAFLD pathology is often evaluated individually. This review attempts to enclose the 
main metabolic and signalling connections between lipotoxic lipid species, and how their homeostasis is 
disrupted in NAFLD.
Keywords: Fatty liver, non-alcoholic fatty liver disease (NAFLD), lipotoxicity, sphingolipid, cholesterol, 
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INTRODUCTION
In 1953, Hokin and Hokin discovered that some lipid 
species located in the cell membrane were able to 
participate in cell signalling.1 Since then, the role of 
lipids in different pathologies has become an intense 
area of research; despite this, the pathogenesis of 
non-alcoholic fatty liver disease (NAFLD) is still 
poorly understood. The most prevalent hypothesis, 
proposed in 1998,2 postulates the convergence of 
two hits, the first consisting of the accumulation 
of lipid droplets or steatosis, followed by the onset 
of the second hit, which induces inflammation and 
tissue damage, defined as steatohepatitis. This 
hypothesis implies that steatosis is a sensitisation 
factor for the reactions of the second hit. Due to 
this preconception, many in vivo dietary studies 
have been performed with unspecific high fat diets, 
sometimes without a lipid composition disclosure 
and often named as ‘Western diets’.3,4 While this is a 
useful approach to achieving some clinical features 
found in patients, such as steatosis, it hampers 
elucidation of the key detrimental lipid species 
that are participating in stress, inflammation, and 
apoptosis signalling pathways. There is compelling 
evidence that hepatic triglycerides (TG) are not 
the effectors of cellular toxicity in NAFLD, but 
rather a defence mechanism to avoid free fatty 
acid (FFA) accumulation, which can trigger cell 
death pathways.5 Likewise, many reports suggest 
an important lipotoxic role of cholesterol and 
sphingolipid species.6,7 
Fatty liver disease therefore has a complex 
pathology, which comprises many concomitant 
cell alterations.8 In patients, plasma serum and 
liver biopsies show different lipid signatures for 
each stage of the pathology.9-12 This connection 
between lipid composition and disease severity 
underscores how important it is to further 
characterise the contribution of these molecules 
to NAFLD pathology and how they interact with 
each other in order to advance treatment and 
prevention strategies.
The purpose of this review is to describe the lipid 
metabolic changes induced by the main lipotoxic 
lipids in NAFLD.
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FATTY ACIDS 
Fatty acids (FA) are carboxylic acids with a 
non-ramified aliphatic chain of different length. 
In mammals, FA usually contain up to 28 carbons 
in even numbers, but the most abundant length in 
biological tissues ranges from 14–20. In addition, 
the presence of one or more double bonds between 
carbons further increases the diversity of these 
molecules. Saturated FA (SFA), with no double 
bonds, account for 30–40% of the FA present in 
animal tissues, in order of abundance: palmitic acid 
(PA) (15–25%), stearic acid (10–20%), myristic acid 
(MA) (0.5–1%), and lauric acid (<0.5%).13
The role of medium-long-chain FA in NAFLD 
has been more extensively studied than shorter 
chain FA (<16 carbons), probably because of the 
faster catabolism of the latter and therefore lower 
evidence of toxic effects in the cell.14 Nowadays, 
it has been demonstrated that FFA species can 
have opposite roles in NAFLD, particularly when 
it comes to comparing SFA with unsaturated 
ones. Buettner et al.15 observed that high fat 
diets with different fatty acid compositions 
triggered different outcomes: a high intake in 
polyunsaturated FA  reduced expression of 
lipogenic genes regulated by sterol regulatory 
element-binding protein 1 (SREBP-1c) and 
increased peroxisome proliferator activated 
receptor (PPAR)-α-regulated lipolytic genes, 
whereas diets rich in SFA and monounsaturated 
FA induced hepatic steatosis. PA is the source of 
FA and ceramide synthesis in the endoplasmic 
reticulum  (ER) of the cell and is also the most 
abundant FA in Western diets. However, an 
intracellular increase in non-esterified PA can be 
fatal, since this molecule induces mitochondrial 
dysfunction,16 lysosomal permeabilisation,17 ER 
stress, and autophagy alteration.18 Similar lipotoxic 
effects have been observed with other 
SFA such as stearic acid.19,20 On the other hand, 
many in vitro studies report that unsaturated 
fats like oleic acid could protect cells against 
PA lipotoxicity.21-23
The line between ‘good’ and ‘bad’ blurs when 
considering insulin resistance in the literature. 
Buettner et al.15 found that an olive oil enriched 
diet led to insulin resistance in rats. Conversely, 
it has been shown that the polyunsaturated FA 
oleic acid, the main olive oil component, has the 
ability to induce PPAR-α thereby promoting FFA 
oxidation, safe storage into TG, and conferring 
protection against insulin resistance.24 Of note, 
studies that report the participation of unsaturated 
fats in insulin resistance are often performed with 
lipid mixtures,25 making it difficult to exclude a 
possible intervention of other lipid species in the 
pathogenic mechanism.
FATTY ACIDS AND SPHINGOLIPIDS 
PA is the precursor of ceramide, the simplest 
sphingolipid, which belongs to a family of lipids 
present in biological membranes and segregated 
in particular domains, where they participate 
in different signalling events. Sphingolipid 
synthesis occurs in the ER and begins with the 
condensation of the amino acid L-serine with PA 
to form 3-ketosphinganine. This first reaction of 
the pathway is achieved by the enzyme serine 
palmitoyltransferase and is the limiting step. 
Afterwards, 3-ketosphinganine reductase reduces 
3-ketosphinganine to sphinganine followed by 
action of dihydroceramide synthase, which adds a 
fatty acid to sphinganine to form dihydroceramide. 
The six dihydroceramide synthase isoforms 
described so far exhibit specificity towards 
different FA, giving rise to heterogeneous ceramide 
species.26 Finally, dihydroceramide desaturase 
(DES) creates a double trans 4,5 bond thereby 
converting dihydroceramide into ceramide. 
Interestingly, Beauchamp et al.27 found that DES 
can be modified by an irreversible lipidation in 
its N-terminal residue with MA through a process 
called myristoylation, which is carried out by 
the enzyme N-myristoyltransferase. Myristoylation 
increases the activity of DES implying that MA, 
a 14 carbon saturated FA present in mammalian 
milk, can potentiate the synthesis of ceramide. 
Once synthesised, ceramide traffics towards 
the Golgi apparatus, where it is modified to 
generate more complex sphingolipids: ceramide 
trafficking, by the ceramide transfer protein to 
the Golgi, is used for sphingomyelin synthesis 
by the enzyme sphingomyelin synthase through 
the addition of a phosphocholine or 
phosphoethanolamine group in the first carbon 
of ceramide with concomitant generation of 
diacylglycerol.28 Alternatively, ceramide can also 
travel to the Golgi apparatus by vesicular transport 
to be converted into glucosylceramide upon 
the addition of glucose by the enzyme 
glucosylceramide synthase. The addition of sialic 
acids to glucosylceramide generates complex 
sphingolipids and gangliosides. Besides the 
aforementioned de novo synthesis, ceramide can 
also be generated from acid (ASM) or neutral (NSM) 
 HEPATOLOGY  •  May 2016   EMJ  EUROPEAN MEDICAL JOURNAL  HEPATOLOGY  •  May 2016   EMJ  EUROPEAN MEDICAL JOURNAL 78 79
sphingomyelinases and from the internalisation 
of membrane sphingolipids through endocytic 
pathways to the lysosomes, where they are 
hydrolysed by sphingomyelinases or glucosidases to 
produce ceramide, a process known as the salvage 
pathway. Many routes therefore converge into the 
generation of ceramide. Importantly, ceramide 
and other sphingolipid species are bioactive lipids 
that contribute to a myriad of cellular processes; 
the alteration of their metabolic homeostasis is a 
potential therapeutic target, based on modulating 
their levels towards a desired functional outcome.29
In a fatty liver scenario, the increase in PA due to 
its higher dietary intake and liver import fuels 
de novo ceramide synthesis. Moreover, PA and 
other SFA can act as toll-like receptor 4 agonists,30 
a signalling pathway shown to induce ceramide 
synthetic enzymes in macrophages,31 but whether 
this occurs in hepatocytes is still under debate.32,33 
PA could also indirectly trigger ceramide synthesis 
through its lipotoxic effects. For example, 
reactive oxygen species or cytokines like tumour 
necrosis factor alpha (TNF-α) lead to a rapid 
accumulation of ceramide through ASM.34 
This event is of particular relevance in lipid rafts, 
membrane microdomains with a high concentration 
of sphingolipids, cholesterol, and signalling 
molecules. The produced ceramide is capable of 
spontaneously self-aggregating and reorganising 
lipid rafts, thereby fusing them and creating large 
signalling platforms. Consequently, ceramide plays 
a crucial role in cellular signalling by clustering 
receptors together.35
Similarly to PA, ceramide accumulation triggers 
lipotoxic pathways like inflammation, ER stress, 
mitochondrial dysfunction and permeabilisation, 
autophagy alteration, and lysosomal cathepsin D 
activation, as reviewed in detail elsewhere.25,36-38 
Some of these pathways can in turn induce 
ceramide and toxic derivatives like gangliosides, 
creating a vicious cycle. On the other hand, 
sphingosine-1-phosphate or ceramide-1-phosphate 
have been reported to be anti-apoptotic and 
mitogenic.29 Recently, an effort has been made to 
decipher the role of different ceramide species 
in cellular signalling. Ceramide C16:0 is toxic 
for macrophages39 but the contrary has been 
observed in human head and neck squamous cell 
carcinomas, where C16:0 was anti-apoptotic and 
C18:0 pro-apoptotic.40 Therefore, the role of 
ceramide species seems to be specific to each cell 
type and further investigation is required to 
characterise their cellular effects.
It is important to note that there is an overlap of 
the targeted organelles and lipotoxic outcomes 
reported with PA and its product ceramide in 
the literature. Since PA can be converted into 
ceramide or trigger ceramide synthesis by other 
means, particular care is suggested before 
attributing lipotoxic roles to PA. In this regard, 
we have recently determined that ER stress is 
aggravated by de novo synthesised ceramide 
after PA treatment in primary hepatocytes.41 
Importantly, we have also validated in vivo the 
potential toxic role of MA when ingested in 
combination with PA through a sustained ceramide 
production, causing serious disruption of lipid 
metabolism homeostasis, ER stress, inflammation, 
and steatohepatitis. 
FATTY ACIDS AND CHOLESTEROL 
Cholesterol is a crucial sterol for animal cell 
membranes. The molecule intercalates between 
phospholipids, positioning the hydroxyl group near 
the polar and the steroid rings in the apolar zones. 
This interaction immobilises and packs the 
membrane, diminishing its fluidity and permeability, 
but at the same time protects the membrane 
against phase transition due to a higher distance 
between aliphatic chains. Besides its structural 
function, cholesterol is highly abundant in lipid 
rafts, where it participates in the formation of 
caveolae, and is the precursor of steroid hormones, 
biliary acids, and vitamin D. 
Synthesis of cholesterol is regulated by its 
availability. The main negative feedback 
mechanism is the inhibition of the sterol 
regulatory element-binding protein 2 (SREBP-2), 
a transcription factor that activates 
cholesterol biosynthetic and uptake enzymes 
like 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase and low-density lipoproteins (LDL), 
respectively. Similarly, cholesterol can also directly 
bind to HMG-CoA reductase to induce its 
degradation by the proteasome.42 A high dietary 
intake of cholesterol therefore reduces its 
endogenous synthesis. This regulation might 
be compromised in case of a concomitant increase 
of other lipid types, mainly TG, which provide 
a source of FA. FA β-oxidation would produce 
acetyl-CoA, required for the first step of de novo 
cholesterol synthesis through the mevalonate 
pathway. However, acetyl-CoA availability is 
controlled by the different subcellular localisation 
of these metabolic pathways, meaning that 
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previous export from the mitochondria to the 
cytosol, through the citrate transporter, is required.43
Cholesterol homeostasis can also be regulated by 
the nuclear receptors liver X receptor (LXR) and 
farnesoid X receptor (FXR). Oxysterols activate 
LXR, inducing the transcription of genes involved 
in cholesterol transport and clearance, thereby 
making it a potential therapeutic target for 
atherosclerosis.44 On the other hand, LXR 
activation also induces lipogenic transcription 
factors like SREBP-1c, meaning that cholesterol 
could indirectly influence steatosis. In the context 
of fatty liver disease, LXR inhibition instead of 
activation may therefore be more beneficial.45 
Ceramide-1-P
GlycosphingolipidsSphingosineSphingosine-1-P
DAG
Triglycerides
MUFA/PUFA
Sphingomyelin
Myristic acid
Palmitic acidCholesterol
Ceramide
Figure 1:  Crosstalk between lipid species in fatty liver disease. 
Lipotoxic lipid species are highlighted in red, dark arrows represent enzymatic reactions, green and red 
arrows refer to changes through stress or metabolic pathways.
MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; DAG: diacylgylcerol.
Figure 2: Pathways affecting lipid homeostasis in non-alcoholic fatty liver disease. 
1) Ca2+ perturbation, ER membrane alteration; 2) TLR4; 3) Mitochondrial dysfunction. 
Transcription factors are highlighted in green and enzymes in purple. 
TLR4: Toll-like receptor 4; DGAT: Diglyceride acyltransferase; MUFA: monounsaturated fatty acids; PUFA: 
polyunsaturated fatty acids; ER: endoplasmic reticulum; ROS: reactive oxygen species; PPAR-α: 
peroxisome proliferator activated receptor alpha; SPT: serine palmitoyltransferase; SREBP: sterol 
regulatory element-binding protein; SMse: sphingomyelinase.
Lipogenesis Lipolysis
SREBP-1c SREBP-1c PPAR-α
SMses/SPT DGATSREBP-2
1 2 3
InflammationER stress ROS
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Cholesterol catabolism into bile acids begins with 
its conversion to 7-α-hydroxycholesterol by 
cholesterol 7-α-monooxygenase (CYP7A1), the 
rate-limiting step of the pathway.46 Bile acids 
bind FXR, which represses CYP7A1, acting as 
a negative feedback loop. Besides its role in 
maintaining the balance between cholesterol and 
bile acids, FXR also induces lipolysis by activating 
PPAR-α and repressing SREBP-1c.47 Accordingly, 
FXR deficiency in mice results in a hepatic and 
serum increase of cholesterol and TG,48 which 
are NAFLD hallmarks. FXR activation by natural 
and synthetic agonists is thus currently regarded 
as one of the main therapeutic strategies for 
NAFLD.49 However, clinical studies show that 
treatment with FXR agonists has some undesired 
side effects such as pruritus or increased LDL 
cholesterol,50 so further research is required to 
develop FXR modulators with a higher specificity 
for lipolytic activity. 
The increase in lipotoxic FFA, such as PA, in the 
fatty liver promotes ER stress, which has been 
shown to activate SREBP-2.51 In relation to this, 
we have recently observed that mice that are fed 
diets with PA or PA plus MA have ER stress, higher 
HMG-CoA reductase gene expression, and hepatic 
cholesterol.41 Curiously, a high intake in MA, which 
is not regarded as lipotoxic per se, has been found 
to affect serum lipoproteins and hepatic cholesterol 
levels.52 The authors attributed this change to a 
negative correlation of MA with the scavenger 
receptor Class B Type I, a high density lipoprotein 
receptor, and cholesterol catabolic enzymes, 
but they did not analyse ER stress markers. 
Moreover, since the authors used a mixture of 
different fats, the participation of other lipid types 
in this outcome cannot be discarded. 
Conversely, an increase in ER membrane 
cholesterol-loading can perturb the organelle 
calcium stores, thereby triggering ER stress and 
engaging in a vicious cycle.53 The unfolded protein 
response induces lipogenic genes expression, 
enhancing the accumulation of FA, lipotoxicity, 
and synthesis of other lipotoxic lipids like 
ceramides. Our group has also reported that 
free cholesterol accumulation can affect 
other organelles like mitochondria, by depleting 
mitochondrial glutathione and sensitising 
hepatocytes to inflammatory cytokines54 and 
lysosomes, by impairing mitophagy and the 
subsequent removal of damaged mitochondria.55
CHOLESTEROL AND SPHINGOLIPIDS 
The relationship between cholesterol and 
sphingolipids has been less directly addressed, 
but these two lipids seem to be tightly regulated. 
Cholesterol preferentially binds to sphingomyelin 
in lipid membranes and concomitant changes in 
their levels have been reported in several studies, 
as reviewed in detail by Ridgway56 and briefly 
synthesised in the following lines. An obvious 
link between cholesterol and sphingomyelin 
is their presence and crucial role in lipid rafts, 
suggesting that a proper ratio is necessary for 
the functioning of these particular membrane 
regions. In fact, a sphingomyelin decrease in the 
plasma membrane by exogenous sphingomyelinase 
treatment downregulates SREBP-2, and induces 
cholesterol esterification and its retrograde 
transport towards the ER. However, it is unclear if 
the local ceramide formation by this sphingomyelin 
hydrolysis participates in the process. In contrast, 
a decrease in cholesterol may not mean a decrease 
in sphingomyelin. This might be due to the need 
for sphingomyelin to continue other important 
functions for the cell and to maintain the 
membrane structure.
An imbalance of these lipids is seen in a number of 
pathologies. Niemann–Pick diseases are inherited 
lysosomal storage disorders with severe metabolic 
and in some cases neurological consequences. 
Acid sphingomyelinase deficiency and resultant 
sphingomyelin accumulation in lysosomes is the 
cause of Niemann–Pick Type A and B, whereas 
Type C (NPC) is caused by NPC 1 or 2 protein 
deficiency, involved in cholesterol efflux from 
lysosomes. A hallmark of all Niemann–Pick 
variants is fatty liver disease, with accumulation of 
sphingomyelin, cholesterol, and other lipid types 
in lysosomal compartments and other cell 
locations.57,58 Due to the close relationship between 
cholesterol and sphingomyelin and because these 
pathologies share common traits, treatment of 
patients with sphingomyelinases could be an 
effective therapy regardless of their genetic defect. 
In fact, NPC patients also have a low ASM activity 
due to secondary sphingomyelin accumulation, 
and treatment with sphingomyelinases has 
proven effective against cholesterol loading in the 
lysosomes of NPC cells.59
Finally, and similarly to SFA, other sphingolipids 
like ceramide and gangliosides could induce 
ER stress,60 thereby activating SREBP-2 and 
cholesterol synthesis, as we have recently observed 
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in vivo.41 Cholesterol levels can therefore be 
influenced by sphingolipids or vice versa and 
further research will be required to discern their 
respective lipotoxic roles in NAFLD.
LIPID HOMEOSTASIS AND GENETIC 
POLYMORPHISMS
Comparative studies of candidate genes in 
NAFLD patients have found some polymorphisms 
associated with an altered lipid metabolism. For 
example, a single nucleotide polymorphism (SNP) 
in the microsomal triglyceride transfer protein 
(MTTP) was identified in its promoter region.61 
MTTP is involved in very low density lipoprotein 
(VLDL) synthesis and export, but patients with 
the SNP variant are predisposed to liver and 
serum TG accumulation due to reduced MTTP 
protein expression. However, experimental design 
with larger cohorts might be required to confirm 
findings in comparative studies, since other works 
often do not report the same correlations.62
Genome-wide association studies have also 
identified different SNPs associated with NAFLD, 
as reviewed in detail by Anstee and Day.63 
Among them, the SNP rs738409 (Ile148Met) in 
the patatin-like phospholipase domain-containing 
3 (PNPLA3) gene is currently the most strongly 
associated with TG accumulation and NAFLD 
biochemical markers. PNPLA3 is a triacylglycerol 
lipase, but curiously the SNP presence is not 
only related to steatosis but also to steatohepatitis 
and fibrosis.64 Further research is therefore 
needed to fully elucidate the mechanisms 
by which this allelic variant promotes such 
pathogenic outcomes.
CONCLUSION
Lipids play a crucial role in cell signalling 
pathways and metabolism. The study of individual 
lipid species is a powerful tool to look for possible 
therapeutic strategies, but it is also important to 
understand the way these molecules’ metabolic 
and signalling pathways are interconnected. 
Figure 1 summarises how the main lipotoxic 
species can affect each other in the context of 
fatty liver and Figure 2 shows the main pathways 
that disrupt lipid homeostasis. NAFLD research 
has evolved towards a hunt for detrimental lipids. 
Considering the interconnectivity summarised 
in this review, in vitro and in vivo studies should 
systematically perform a detailed quantification 
of lipid species and metabolic gene expression, 
which should be regarded as necessary as 
assessing transaminases in serum. For that 
purpose, lipidomics have become crucial in 
identifying changes in a myriad of these molecules 
with high sensitivity,65 thereby providing the basis 
to look for molecular pathogenic mechanisms.
Further work needs to be done to fully elucidate 
NAFLD complexity,66 but it is clear that its 
inherent lipid accumulation translates into a 
lipid homeostasis dysregulation, with many lipid 
types being affected simultaneously and more 
importantly, many of them having specific 
biological functions.
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